Compare AMPH & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPH | THQ |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 885.4M | 779.0M |
| IPO Year | 2005 | N/A |
| Metric | AMPH | THQ |
|---|---|---|
| Price | $18.72 | $18.55 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.38 | N/A |
| AVG Volume (30 Days) | ★ 421.7K | 287.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | N/A |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $134.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.65 | $15.14 |
| 52 Week High | $31.26 | $20.39 |
| Indicator | AMPH | THQ |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 47.14 |
| Support Level | $18.92 | $18.33 |
| Resistance Level | $19.99 | $18.98 |
| Average True Range (ATR) | 0.69 | 0.25 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 27.58 | 27.85 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.